Isolation of oxygen-dependent nicotine- and pseudooxynicotine-metabolizing enzymes

For decades, scientists have been searching for a biological way to break the grip of nicotine addiction. The idea is simple: if you could introduce an enzyme into the body that rapidly destroys nicotine before it reaches the brain, the urge to smoke might vanish. Nature has already provided a candidate for this job. A bacterium found in soil, Pseudomonas putida, produces an enzyme called NicA2 that can convert nicotine into a harmless substance. However, this natural version has a major flaw. Inside the bacterium, the enzyme works like a specialized machine that needs a specific partner, a tiny protein called a cytochrome, to function. Without that partner, the enzyme is incredibly slow, reacting with oxygen so sluggishly that it would require massive, impractical doses to work in a human patient. Researchers have tried to fix this by tweaking the enzyme's structure in the lab, making it faster, but they have hit a wall. The enzyme simply refuses to get much faster at using oxygen on its own.

To find a better solution, a team of researchers decided to stop trying to fix the old machine and instead look for a new one entirely. They went hunting in the soil and tobacco waste for bacteria that could eat nicotine as their only food source, hoping to find a naturally evolved enzyme that works efficiently with oxygen. They found exactly what they were looking for in a strain of bacteria named Peribacillus frigoritolerans NIC8. This microbe, isolated from an unsmoked cigarette, possesses a unique set of enzymes that act as true oxidizers. Unlike the slow, partner-dependent NicA2, these new enzymes, named Ncox and Pnox, can grab nicotine and its chemical cousin, pseudooxynicotine, and break them down rapidly using only the oxygen in the air. The speed at which they work is nearly a thousand times faster than the original NicA2 when oxygen is the fuel, offering a promising new path for treating addiction.

The journey began with a simple observation. The researchers took samples from tobacco fields and cigarette butts, placing them on plates where nicotine was the only food available. Most bacteria starved, but one colony grew robustly. Genetic analysis identified this survivor as a strain of Peribacillus frigoritolerans, a species previously known to exist but not known for eating nicotine. When the researchers removed a specific 123,000-base-pair ring of DNA, known as a plasmid, from the bacteria, the organism immediately lost its ability to grow on nicotine. This proved that the secret to its diet was encoded on this extra piece of genetic material. Inside that plasmid, the team found two genes sitting right next to each other, which they named ncox and pnox. These genes produced enzymes that looked similar to the famous NicA2 but were distinct enough to suggest they had evolved separately.

To understand how these enzymes worked, the team produced them in the lab using E. coli bacteria and watched them in action. They observed that when the Ncox enzyme met nicotine, it turned from yellow to clear almost instantly, a visual sign that it was chemically changing the nicotine. The Pnox enzyme did the same thing when it met pseudooxynicotine, a substance that forms naturally when the first product of nicotine breakdown sits in the air. Crucially, neither enzyme needed a partner protein to do this; they worked directly with the oxygen in the air. When the researchers measured the speed of this reaction, they found that Ncox could process nicotine at a rate of 7.7 times per second, while Pnox processed its target at 3.9 times per second. These numbers are vastly superior to the original NicA2, which manages only about 0.007 reactions per second when left to work with oxygen alone.

The researchers also looked at how these enzymes handle the oxygen molecule itself. In a process called transient kinetics, they mixed the enzymes with oxygen in a rapid-flow machine to measure the exact speed of the reaction. They found that Ncox and Pnox react with oxygen at rates of 51,100 and 81,000 per second per unit of concentration, respectively. These rates are comparable to other highly efficient enzymes in nature that are known to be true oxidizers, and they are thousands of times faster than NicA2. This confirmed that the new enzymes are not just slightly improved versions of the old ones, but fundamentally different machines designed by evolution to work in an oxygen-rich environment without needing a cytochrome partner.

To prove that these enzymes could actually replace the missing partner in a biological system, the team performed a rescue experiment. They took a strain of the original Pseudomonas putida bacteria that had been genetically modified to lack its cytochrome partner, rendering it unable to eat nicotine. When they gave this crippled bacteria the gene for the new Ncox enzyme, the bacteria immediately regained the ability to grow on nicotine. In fact, the bacteria grew faster with the new Ncox enzyme than they did with the best laboratory-evolved version of the old NicA2. This demonstrated that the new enzyme could function independently and efficiently in a living system, bypassing the need for the complex cellular machinery that the original enzyme required.

The study also revealed how the bacteria regulates these enzymes. By comparing the bacteria's genetic activity when grown on nicotine versus when grown on a different food source, the researchers saw that the genes for Ncox and Pnox were turned on high when nicotine was present. This suggests that the bacteria naturally uses these enzymes to digest nicotine when it encounters it in its environment. The genetic analysis further showed that these enzymes likely evolved from a common ancestor found in other bacteria, but they took a different evolutionary path than the NicA2 found in soil bacteria. While NicA2 remained tied to the cytochrome system, these new enzymes in the Peribacillus evolved to use oxygen directly, perhaps because the specific environment they inhabit favored this simpler, faster method.

The implications of this discovery are significant for the future of addiction treatment. The primary goal of using enzymes to treat nicotine addiction is to clear the drug from the bloodstream quickly enough to prevent the brain from feeling the high. The original NicA2 enzyme was too slow to do this without requiring enormous doses that would be difficult and expensive to produce. The new Ncox enzyme, with its ability to work rapidly with oxygen, offers a much more practical solution. It is a naturally occurring, highly efficient tool that does not require the complex cellular partners that limit the performance of its predecessors. While the researchers note that the enzyme still needs further testing to see if it can be optimized for human use, the discovery provides a powerful new candidate that nature has already refined to work at the speed necessary for a therapeutic effect.